P2Y12受体抑制剂替格瑞洛临床效应的研究进展

Research Progress on Clinical Effects of P2Y12 Receptor Inhibitor Ticagrelor

替格瑞洛是一种新的P2Y12受体抑制剂,与氯吡格雷相比,它具有更强效、更快速及可逆抑制血小板的特点,并且由于替格瑞洛本身具有活性,无需经过肝酶转化,所以对于氯吡格雷无反应或低反应的患者,替格瑞洛能够更好的防止缺血事件的发生。现就P2Y12受体抑制剂替格瑞洛的化学成分、药效学、药代动力学及其临床效应的最新研究进展做一综述。

Compared with clopidogrel,ticagrelor is a novel P2Y12 receptor inhibitor,it is more potent,faster and reversible inhibition of platelet,and due to ticagrelor itself has activity,without liver enzyme conversion. Ticagrelor do better in prevent ischemic event for the patients who has no response or low response to clopidogrel. The focus of this article is to review the latest research progress of P2Y12 receptor inhibitor ticagrelor chemistry,pharmacodynamics,pharmacokinetics and clinical effects.